Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

moxifloxacin Ophthalmic Solution [Vigamox]

National Institutes of Health

Related topics

Related topics

3 relations
Ophthalmic SolutionVigamox

Narrower (1)

moxifloxacin 5 MG/ML Ophthalmic Solution [Vigamox]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
BackgroundDry eye disease (DED) is a prevalent complication of diabetes and presents as reduced tear production and/or increased… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin
The objective of this research was to develop and evaluate an ocular insert for the controlled drug delivery of moxifloxacin… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Comparison of cytotoxicity of fluoroquinolone antimicrobial eye drops and its effect on their bioavailability
In addition to the breadth of activity of antibacterial medications as well as to their pharmacokinetic and pharmacodynamic… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
A comparative evaluation of antimicrobial eye drops cytotoxicity
In addition to the spectrum of antibacterial activity of antimicrobial medicines and their pharmacokinetic and pharmacodynamic… 
2009
2009
Moxifloxacin intrakameral: Eine sichere Option zur Endophthalmitisprophylaxe?
ZusammenfassungHintergrundDie Wirksamkeit von Moxifloxacin (Vigamox®) umfasst die meisten für bakterielle Endophthalmitiden… 
2004
2004
Human Aqueous Humor Concentrations of Moxifloxacin Following Two Multiple–Dose Topical Ocular Dosing Regimens of Vigamox®.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE